Intussusception and Other Adverse Event Surveillance after Pilot Introduction of Rotavirus Vaccine in Nam Dinh and Thua Thien Hue Provinces—Vietnam, 2017–2021
Ly Khanh Thi Le,
Thao Phuong Thi Pham,
Le Thi Phuong Mai,
Quyet Tu Nguyen,
Mai Phuong Ngoc Tran,
Thien Huu Ho,
Hung Hoang Pham,
Sanh Van Le,
Ha Ngoc Hoang,
Anh Tuan Lai,
Nguyen Thuy Huong,
Hien Dang Nguyen,
Dang Duc Anh,
Makiko Iijima,
Umesh D. Parashar,
Nguyen Van Trang,
Jacqueline E. Tate
Affiliations
Ly Khanh Thi Le
National Institute of Hygiene and Epidemiology, Hanoi 100000, Vietnam
Thao Phuong Thi Pham
Center for Research and Production of Vaccines and Biologicals, Hanoi 100000, Vietnam
Le Thi Phuong Mai
National Institute of Hygiene and Epidemiology, Hanoi 100000, Vietnam
Quyet Tu Nguyen
National Institute of Hygiene and Epidemiology, Hanoi 100000, Vietnam
Mai Phuong Ngoc Tran
National Institute of Hygiene and Epidemiology, Hanoi 100000, Vietnam
Thien Huu Ho
Central Hue Hospital, Thua Thien Hue 530000, Vietnam
Hung Hoang Pham
Central Hue Hospital, Thua Thien Hue 530000, Vietnam
Sanh Van Le
Hue Center for Disease Control, Thua Thien Hue 530000, Vietnam
Ha Ngoc Hoang
Nam Dinh General Hospital, Nam Dinh 420000, Vietnam
Anh Tuan Lai
Nam Dinh Center for Disease Control, Nam Dinh 420000, Vietnam
Nguyen Thuy Huong
Center for Research and Production of Vaccines and Biologicals, Hanoi 100000, Vietnam
Hien Dang Nguyen
Center for Research and Production of Vaccines and Biologicals, Hanoi 100000, Vietnam
Dang Duc Anh
National Institute of Hygiene and Epidemiology, Hanoi 100000, Vietnam
Makiko Iijima
World Health Organization, Vietnam Office, Hanoi 100000, Vietnam
Umesh D. Parashar
United States Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
Nguyen Van Trang
National Institute of Hygiene and Epidemiology, Hanoi 100000, Vietnam
Jacqueline E. Tate
United States Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
Rotavin-M1 (POLYVAC) was licensed in Vietnam in 2012. The association of Rotavin-M1 with intussusception, a rare adverse event associated with rotavirus vaccines, and with adverse events following immunization (AEFI) have not been evaluated and monitored under conditions of routine use. From February 2017 to May 2021, we conducted a pilot introduction of Rotavin-M1 into the routine vaccination program in two provinces. Surveillance for intussusception was conducted at six sentinel hospitals. AEFI reports at 30 min and 7 days after vaccination were recorded. Among 443 children ®, ComBE Five®) compared to Rotavin-M1 without pentavalent vaccines. There was no association between intussusception and Rotavin-M1. The vaccine was generally safe when administered alone and when co-administered with other vaccines.
